Shattuck Labs Inc (STTK)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$5.53

+0.20 (+3.75%)

Market Cap: $530.92M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

71%(17/24)

Avg Surprise

-5.25%

Streak

6 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.11

Range$-0.16 - $-0.08

10 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.12+12.9%

60d ago$-0.12+6.8%

30d ago$-0.11-0.9%

7d ago$-0.11-0.9%

Current$-0.11

Revenue Consensus

$33330

Range$0 - $300000

9 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.12

Range$-0.50 - $0.02

10 analysts

Revenue Consensus

$88890

Range$-33330 - $1M

9 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.12	$-0.50 - $0.02	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$-0.11	$-0.16 - $-0.08	-	-	10	2 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 11, 2026Reported Aug 11	$-0.12	$-0.14	$-0.18 - $-0.08	+14.29%	Beat	9	1 1 30d	+50.0%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.13	$-0.13	$-0.17 - $-0.11	+0.00%	Beat	5	1 0 30d	+51.9%
Dec 31, 2025Dec 25 Reported Mar 5, 2026Reported Mar 5	$-0.12	$-0.13	$-0.17 - $-0.09	+8.81%	Beat	6	1 1 30d	+67.6%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-0.14	$-0.15	$-0.22 - $-0.09	+6.67%	Beat	6	4 0 30d	+57.6%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-0.24	$-0.24	$-0.29 - $-0.21	+0.00%	Beat	4	0 2 30d	+42.9%
Mar 31, 2025Mar 25 Reported May 1, 2025Reported May 1	$-0.27	$-0.28	$-0.40 - $-0.22	+4.42%	Beat	4	0 2 30d	+27.0%
Dec 31, 2024Dec 24 Reported Mar 27, 2025Reported Mar 27	$-0.37	$-0.32	$-0.46 - $-0.24	-15.63%	Miss	5	3 1 30d	+9.8%
Sep 30, 2024Sep 24 Reported Nov 14, 2024Reported Nov 14	$-0.33	$-0.42	$-0.49 - $-0.35	+21.43%	Beat	4	No revisions (30d)	+49.2%
Jun 30, 2024Jun 24 Reported Aug 1, 2024Reported Aug 1	$-0.42	$-0.41	$-0.45 - $-0.38	-2.44%	Miss	5	No revisions (30d)	+16.0%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$-0.37	$-0.45	$-0.52 - $-0.38	+17.78%	Beat	5	1 0 30d	+24.5%
Dec 31, 2023Dec 23 Reported Feb 29, 2024Reported Feb 29	$-0.41	$-0.57	$-0.68 - $-0.51	+28.07%	Beat	5	No revisions (30d)	+31.7%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$-0.65	$-0.52	$-0.55 - $-0.46	-25.00%	Miss	6	No revisions (30d)	-12.1%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.50	$-0.52	$-0.53 - $-0.50	+3.85%	Beat	5	No revisions (30d)	+23.1%
Mar 31, 2023Mar 23 Reported May 9, 2023Reported May 9	$-0.49	$-0.63	$-0.67 - $-0.58	+22.22%	Beat	5	No revisions (30d)	+15.5%
Dec 31, 2022Dec 22 Reported Feb 23, 2023Reported Feb 23	$-0.60	$-0.63	$-0.69 - $-0.59	+4.76%	Beat	5	No revisions (30d)	-433.3%
Sep 30, 2022Sep 22 Reported Nov 8, 2022Reported Nov 8	$-0.58	$-0.67	$-0.69 - $-0.66	+13.43%	Beat	5	No revisions (30d)	-41.5%
Jun 30, 2022Jun 22 Reported Aug 11, 2022Reported Aug 11	$-0.65	$-0.59	$-0.64 - $-0.56	-10.17%	Miss	4	No revisions (30d)	-16.1%
Mar 31, 2022Mar 22 Reported May 12, 2022Reported May 12	$-0.58	$-0.50	$-0.58 - $-0.42	-16.00%	Miss	3	No revisions (30d)	-107.1%
Dec 31, 2021Dec 21 Reported Mar 15, 2022Reported Mar 15	$0.18	N/A	-	+141.86%	Beat	2	No revisions (30d)	+158.1%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$-0.41	$-0.44	$-0.45 - $-0.44	+6.82%	Beat	2	No revisions (30d)	+73.4%
Jun 30, 2021Jun 21 Reported Aug 11, 2021Reported Aug 11	$-0.56	$-0.35	$-0.36 - $-0.34	-60.00%	Miss	2	No revisions (30d)	-55.5%
Mar 31, 2021Mar 21 Reported May 10, 2021Reported May 10	$-0.28	$-0.39	$-0.41 - $-0.37	+28.21%	Beat	3	No revisions (30d)	-
Dec 31, 2020Dec 20 Reported Mar 15, 2021Reported Mar 15	$-0.31	$-0.39	$-0.42 - $-0.36	+20.51%	Beat	3	No revisions (30d)	-
Sep 30, 2020Sep 20 Reported Oct 13, 2020Reported Oct 13	$-1.54	$-0.35	$-0.39 - $-0.31	-340.00%	Miss	3	No revisions (30d)	-
Jun 30, 2020Jun 20 Reported Sep 2, 2020Reported Sep 2	$-0.36	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-10.84	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-5570.00%
ROE	-39.20%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	27.59x	Quick Ratio	27.59x
Trading Statistics
Beta	1.10	Avg Volume	1.65M
52-Week High	$8.33	52-Week Low	$1.72

Technical Indicators Dashboard

Moving Averages

SMA 10$5.88

SMA 20$6.14

SMA 50$6.66

SMA 200$5.96

EMA 10$5.82

EMA 20$6.06

EMA 50$6.38

EMA 200$5.67

MACD

Line: -0.28Signal: -0.21Hist: -0.07

ADX

ADX: 20.8+DI: 16.6-DI: 29.4

Aroon & PSAR

Aroon Up56.0

Aroon Down96.0

PSAR$6.76

Bollinger Bands

Upper Band$7.05

Lower Band$5.23

%B Position2963%(Upper)

Band Width0.16

RSI (14-Day)

Neutral

38.7

Momentum Oscillators

Stoch %K8.3

Stoch %D14.7

Williams %R-84.8

ROC (10d)-19.2%

Momentum-1.31

CCI (20d)-125.5

MFI (14d)50.2

Volatility Measures

ATR (14d)$0.45(8.1%)

StdDev (20d)0.45

Hist Vol73.2%(High)

Volume Flow

VWAP$5.47

OBV145.9M

AD Line-18.8M

CMF (20d)-0.067

Volume Metrics

Avg Vol (20d)1.7M

Vol Ratio0.5x(Low)

VWMA (20d)$6.17

Pivot Points

R3$5.83

R2$5.67

R1$5.50

Pivot Point$5.35

S1$5.17

S2$5.02

S3$4.85

Advanced Oscillators

TSI-19.75

Ultimate Osc46.2

KST-105.92

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$1.00M	$0	$0	$34.70M	$3.00M	$1.61M	$1.11M	$714,000	$686,000
Cost of Revenue	$0	$0	$906,000	$0	$0	$0	$20.21M	$0	$0	$0	$981,000	$0
Gross Profit	$0	$0	$-906,000	$1.00M	$0	$0	$14.49M	$3.00M	$1.61M	$1.11M	$714,000	$686,000

Operating Expenses	$16.16M	$15.54M	$13.37M	$11.72M	$13.03M	$14.39M	$19.64M	$20.92M	$24.57M	$21.16M	$19.66M	$29.28M
R&D	$11.70M	$10.95M	$9.06M	$7.62M	$8.68M	$9.92M	$15.39M	$16.31M	$19.24M	$16.26M	$15.23M	$24.21M
SG&A	$4.46M	$4.60M	$4.32M	$4.10M	$4.35M	$4.47M	$4.25M	$4.60M	$5.33M	$4.89M	$4.44M	$5.07M
Operating Income	$-16,155,000	$-15,545,000	$-13,371,000	$-10,716,000	$-13,032,000	$-14,389,000	$-19,641,000	$-17,920,000	$-22,962,000	$-20,044,000	$-18,951,000	$-28,598,000

Interest Income	$1.03M	$779,000	$0	$0	$804,000	$689,000	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-15,152,000	$-14,767,000	$-12,593,000	$-10,056,000	$-12,458,000	$-13,702,000	$-18,679,000	$-16,675,000	$-21,552,000	$-18,504,000	$-17,687,000	$-27,541,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-15,152,000	$-14,767,000	$-12,593,000	$-10,056,000	$-12,458,000	$-13,702,000	$-18,679,000	$-16,675,000	$-21,552,000	$-18,504,000	$-17,687,000	$-27,541,000

EBITDA	$-15,525,000	$-14,703,000	$-14,676,000	$-9,305,000	$-12,332,000	$-13,457,000	$-23,334,000	$-16,464,000	$-21,207,000	$-17,901,000	$-21,803,000	$-27,072,000
EBIT	$-16,181,000	$-15,546,000	$-15,296,000	$-10,056,000	$-13,262,000	$-14,391,000	$-23,853,000	$-16,675,000	$-21,552,000	$-18,504,000	$-22,356,000	$-27,541,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about STTK

News

UBS upgrades Shattuck Labs stock to strong buy at USD 17 target

UBS has upgraded Shattuck Labs (STTK) stock to a "strong buy" rating with a USD 17.00 price target, citing the company's SL-325 program. This upgrade follows previous "buy" ratings and price target increases from other...

ad-hoc-news.de•Oct 15, 2026 8:41 PM ET10/15/26•Bullish

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

Shattuck Labs, Inc. (NASDAQ: STTK) announced two poster presentations at United European Gastroenterology (UEG) Week 2026. The presentations will detail the development of SL-846...

GlobeNewswire•Oct 13, 2026 11:11 PM ET10/13/26•Somewhat-Bullish

Shattuck Labs to present new antibody research at UEG Week 2026 in Barcelona

Shattuck Labs announced two poster presentations at the United European Gastroenterology (UEG) Week 2026 in Barcelona. These presentations will highlight their novel bispecific antibody SL-846 for inflammatory diseases...

Pluang•Oct 13, 2026 8:42 AM ET10/13/26•Bullish

UBS Initiates Shattuck Labs at Buy With $17 Price Target

UBS has initiated coverage on Shattuck Labs (NASDAQ:STTK) with a Buy rating and a $17 price target. The firm's positive outlook suggests confidence in Shattuck Labs' potential growth and market performance. This...

Moomoo•Oct 13, 2026 12:10 AM ET10/13/26•Bullish

STTK Initiated Coverage by UBS -- Rating Set to Buy with PT $17.

UBS has initiated coverage on Shattuck Labs (STTK) with a Buy rating and a price target of $17.00. Despite this positive analyst rating...

GuruFocus•Oct 12, 2026 10:12 AM ET10/12/26•Somewhat-Bullish

STTK Valuation and Fair Value

P/E: -10.8x
P/B: 3.4x

See GNG's fair value

STTK Profitability: Margins, ROIC and FCF

Operating margin: -5570.0%
Net margin: 0.0%
ROE: -39.2%
FCF margin: -4116.2%

STTK Competitors

Company	Ticker
Bright Minds Biosciences Inc	DRUG
Puma Biotechnology Inc	PBYI
ZimVie Inc	ZIMV
Evolent Health Inc	EVH
Valneva SE ADR	VALN
Oncology Institute Inc	TOI
Silence Therapeutics PLC	SLN
Delcath Systems Inc	DCTH

Sector: Healthcare

STTK Analyst Ratings

Consensus: Buy
Analysts: 11
Strong Buy: 3
Buy: 8
Hold: 0
Sell: 0
Strong Sell: 0

STTK Bull Case vs Bear Case

Bull case

100.0% of STTK's analyst ratings are Buy or Strong Buy.

Bear case

STTK's quarterly revenue changed -66.6% year over year.

STTK Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 5.0%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.11
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 1 down

Frequently Asked Questions About STTK

Does STTK pay dividends?

Shattuck Labs Inc (STTK) does not currently pay a regular dividend.

What is STTK's market cap?

Shattuck Labs Inc (STTK) has a market capitalization of $530.92M with a current stock price of $5.53.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In